semaglutide and binge eating disorder 504: Adult Disorders in the GLP-1 Era What is binge eating disorder?|

The risk of developing these severe side effects is very small, but it is important that patients and healthcare professionals are aware and alert to the associated symptoms. An estimated 1.6 million UK adults used GLP-1s such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro) to lose weight between early 2024 and early 2025, with an additional 3.3 million interested in using weight loss drugs during 2026

Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, et al

10.1136/bmjopen-2021-060668 111

The Role of Genetic Insights in Personalizing GLP-1 Selection Recent evidence suggests genetic variants in GLP-1 receptor, GIP receptor, and appetite-regulation pathways may influence individual response patterns to incretin-based therapies

It takes time before you see results from this treatment